Novel vasodilators in heart failure

Current Heart Failure Reports

Volumn 10, Issue 1, 2013, Pages 1-11

  Zamani, Payman ^a   Greenberg, Barry H ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Guanylate cyclase; Heart failure; Natriuretic; Relaxin; Vasodilator

Indexed keywords

ATRIAL NATRIURETIC FACTOR; ATRIAL NATRIURETIC FACTOR ALPHA; BRAIN NATRIURETIC PEPTIDE; CINACIGUAT; DENDROASPIS NATRIURETIC PEPTIDE; INOTROPIC AGENT; LOOP DIURETIC AGENT; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE TYPE C; PLACEBO; RELAXIN; SERELAXIN; UNCLASSIFIED DRUG; URODILATIN; VASODILATOR AGENT;

ACUTE HEART FAILURE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIAC PATIENT; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG RESPONSE; DYSPNEA; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INDEX; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LOW DRUG DOSE; MORTALITY; NONHUMAN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PULMONARY ARTERY OCCLUSION PRESSURE; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HEART FAILURE;

EID: 84871889946     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-012-0126-4     Document Type: Article

References (110)

1. •• Gassanov N, Biesenbach E, Caglayan E, Nia A, Fuhr U, Er F. Natriuretic peptides in therapy for decompensated heart failure. Eur J Clin Pharmacol. 2012;68:223-30. Excellent review of the natriuretic peptide system including a discussion on the use of recombinant BNP (nesiritide).
2. Ruskoaho H. Atrial natriuretic peptide: synthesis, release, and metabolism. Pharmacol Rev. 1992;44:479-602.
3. D'Souza SP, Davis M, Baxter GF. Autocrine and paracrine actions of natriuretic peptides in the heart. Pharmacol Ther. 2004;101:113-29.
4. Schirger JA, Heublein DM, Chen HH, Lisy O, Jougasaki M, Wennberg PW, Burnett Jr JC. Presence of dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human heart failure. Mayo Clin Proc. 1999;74:126-30.
5. Richards AM, Lainchbury JG, Nicholls MG, Cameron AV, Yandle TG. Dendroaspis natriuretic peptide: endogenous or dubious? Lancet. 2002;359:5-6.
6. Mitrovic V, Hernandez AF, Meyer M, Gheorghiade M. Role of guanylate cyclase modulators in decompensated heart failure. Heart Fail Rev. 2009;14:309-19.
7. Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S, Chepenik KP, Waldman SA. Guanylyl cyclases and signaling by cyclic gmp. Pharmacol Rev. 2000;52:375-414.
8. Singh G, Kuc RE, Maguire JJ, Fidock M, Davenport AP. Novel snake venom ligand Dendroaspis natriuretic peptide is selective for natriuretic peptide receptor-a in human heart: downregulation of natriuretic peptide receptor-a in heart failure. Circ Res. 2006;99:183-90.
9. Vesely DL. Urodilatin: a better natriuretic peptide? Curr Heart Fail Rep. 2007;4:147-52.
10. Suga S, Nakao K, Hosoda K, Mukoyama M, Ogawa Y, Shirakami G, Arai H, Saito Y, Kambayashi Y, Inouye K, et al. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and c-type natriuretic peptide. Endocrinology. 1992;130:229-39.
11. Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev. 2006;27:47-72.
12. Schweitz H, Vigne P, Moinier D, Frelin C, Lazdunski M. A new member of the natriuretic peptide family is present in the venom of the green mamba (dendroaspis angusticeps). J Biol Chem. 1992;267:13928-32.
13. Forssmann W, Meyer M, Forssmann K. The renal urodilatin system: clinical implications. Cardiovasc Res. 2001;51:450-62.
14. Chen HH, Lainchbury JG, Burnett Jr JC. Natriuretic peptide receptors and neutral endopeptidase in mediating the renal actions of a new therapeutic synthetic natriuretic peptide dendroaspis natriuretic peptide. J Am Coll Cardiol. 2002;40:1186-91.
15. Das BB, Solinger R. Role of natriuretic peptide family in cardiovascular medicine. Cardiovasc Hematol Agents Med Chem. 2009;7:29-42.
16. Lee CY, Burnett Jr JC. Natriuretic peptides and therapeutic applications. Heart Fail Rev. 2007;12:131-42.
17. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321-8.
18. Bestle MH, Olsen NV, Christensen P, Jensen BV, Bie P. Cardiovascular, endocrine, and renal effects of urodilatin in normal humans. Am J Physiol. 1999;276:R684-95.
19. Stevens TL, Burnett Jr JC, Kinoshita M, Matsuda Y, Redfield MM. A functional role for endogenous atrial natriuretic peptide in a canine model of early left ventricular dysfunction. J Clin Invest. 1995;95:1101-8.
20. O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer GM, Komajda M, Massie BM, McMurray JJ, Nieminen MS, Reist CJ, Rouleau JL, Swedberg K, Adams Jr KF, Anker SD, Atar D, Battler A, Botero R, Bohidar NR, Butler J, Clausell N, Corbalan R, Costanzo MR, Dahlstrom U, Deckelbaum LI, Diaz R, Dunlap ME, Ezekowitz JA, Feldman D, Felker GM, Fonarow GC, Gennevois D, Gottlieb SS, Hill JA, Hollander JE, Howlett JG, Hudson MP, Kociol RD, Krum H, Laucevicius A, Levy WC, Mendez GF, Metra M, Mittal S, Oh BH, Pereira NL, Ponikowski P, Tang WH, Tanomsup S, Teerlink JR, Triposkiadis F, Troughton RW, Voors AA, Whellan DJ, Zannad F, Califf RM. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365:32-43.
21. Chen HH, Glockner JF, Schirger JA, Cataliotti A, Redfield MM, Burnett Jr JC. Novel protein therapeutics for systolic heart failure: chronic subcutaneous b-type natriuretic peptide. J Am Coll Cardiol. 2012;60:2305-12.
22. Cody RJ, Atlas SA, Laragh JH, Kubo SH, Covit AB, Ryman KS, Shaknovich A, Pondolfino K, Clark M, Camargo MJ, et al. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest. 1986;78:1362-74.
23. Ishikawa C, Tsutamoto T, Wada A, Fujii M, Ohno K, Sakai H, Yamamoto T, Horie M. Inhibition of aldosterone and endothelin-1 by carperitide was attenuated with more than 1 week of infusion in patients with congestive heart failure. J Cardiovasc Pharmacol. 2005;46:513-8.
24. Hayashi M, Tsutamoto T, Wada A, Maeda K, Mabuchi N, Tsutsui T, Horie H, Ohnishi M, Kinoshita M. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol. 2001;37:1820-6.
25. Shono M, Yoshimura M, Nakayama M, Yamamuro M, Abe K, Suzuki S, Mizuno Y, Sugiyama S, Saito Y, Nakao K, Yasue H, Ogawa H. Predominant effect of a-type natriuretic peptide on reduction of oxidative stress during the treatment of patients with heart failure. Circ J. 2007;71:1040-6.
26. Fifer MA, Molina CR, Quiroz AC, Giles TD, Herrmann HC, De Scheerder IR, Clement DL, Kubo S, Cody RJ, Cohn JN, et al. Hemodynamic and renal effects of atrial natriuretic peptide in congestive heart failure. Am J Cardiol. 1990;65:211-6.
27. Weidmann P, Hasler L, Gnadinger MP, Lang RE, Uehlinger DE, Shaw S, Rascher W, Reubi FC. Blood levels and renal effects of atrial natriuretic peptide in normal man. J Clin Invest. 1986;77:734-42.
28. Saito Y, Nakao K, Nishimura K, Sugawara A, Okumura K, Obata K, Sonoda R, Ban T, Yasue H, Imura H. Clinical application of atrial natriuretic polypeptide in patients with congestive heart failure: beneficial effects on left ventricular function. Circulation. 1987;76:115-24.
29. Suwa M, Seino Y, Nomachi Y, Matsuki S, Funahashi K. Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the 'real world' of therapy. Circ J. 2005;69:283-90.
30. Nomura F, Kurobe N, Mori Y, Hikita A, Kawai M, Suwa M, Okutani Y. Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure: compass: carperitide effects observed through monitoring dyspnea in acute decompensated heart failure study. Circ J. 2008;72:1777-86.
31. Hata N, Seino Y, Tsutamoto T, Hiramitsu S, Kaneko N, Yoshikawa T, Yokoyama H, Tanaka K, Mizuno K, Nejima J, Kinoshita M. Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the protect multicenter randomized controlled study. Circ J. 2008;72:1787-93.
32. Nishi K, Sato Y, Miyamoto T, Toma M, Taniguchi R, Fukuhara R, Saijo S, Fujiwara H, Takatsu Y. Intermittent infusions of carperitide or inotoropes in out-patients with advanced heart failure. J Cardiol. 2012;59:366-73.
33. Hisatomi K, Eishi K. Multicenter trial of carperitide in patients with renal dysfunction undergoing cardiovascular surgery. Gen Thorac Cardiovasc Surg. 2012;60:21-30.
34. Sezai A, Hata M, Niino T, Yoshitake I, Unosawa S, Wakui S, Kimura H, Shiono M, Takayama T, Hirayama A. Results of low-dose human atrial natriuretic peptide infusion in nondialysis patients with chronic kidney disease undergoing coronary artery bypass grafting: the nu-hit (Nihon university working group study of low-dose hanp infusion therapy during cardiac surgery) trial for ckd. J Am Coll Cardiol. 2011;58:897-903.
35. Yoshitake I, Sezai A, Hata M, Niino T, Unosawa S, Wakui S, Shiono M. Low-dose atrial natriuretic peptide for chronic kidney disease in coronary surgery. Ann Thorac Cardiovasc Surg. 2011;17:363-8.
36. Mitaka C, Kudo T, Haraguchi G, Tomita M. Cardiovascular and renal effects of carperitide and nesiritide in cardiovascular surgery patients: a systematic review and meta-analysis. Crit Care. 2011;15:R258.
37. Meyer M, Richter R, Brunkhorst R, Wrenger E, Schulz-Knappe P, Kist A, Mentz P, Brabant EG, Koch KM, Rechkemmer G, Forssmann WG. Urodilatin is involved in sodium homeostasis and exerts sodium-state-dependent natriuretic and diuretic effects. Am J Physiol. 1996;271:F489-97.
38. Goetz K, Drummer C, Zhu JL, Leadley R, Fiedler F, Gerzer R. Evidence that urodilatin, rather than anp, regulates renal sodium excretion. J Am Soc Nephrol. 1990;1:867-74.
39. Saxenhofer H, Raselli A, Weidmann P, Forssmann WG, Bub A, Ferrari P, Shaw SG. Urodilatin, a natriuretic factor from kidneys, can modify renal and cardiovascular function in men. Am J Physiol. 1990;259:F832-8.
40. Carstens J, Jensen KT, Pedersen EB. Metabolism and action of urodilatin infusion in healthy volunteers. Clin Pharmacol Ther. 1998;64:73-86.
41. Dorner GT, Selenko N, Kral T, Schmetterer L, Eichler HG, Wolzt M. Hemodynamic effects of continuous urodilatin infusion: a dose-finding study. Clin Pharmacol Ther. 1998;64:322-30.
42. Mitrovic V, Luss H, Nitsche K, Forssmann K, Maronde E, Fricke K, Forssmann WG, Meyer M. Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial. Am Heart J. 2005;150:1239.
43. Mitrovic V, Seferovic PM, Simeunovic D, Ristic AD, Miric M, Moiseyev VS, Kobalava Z, Nitsche K, Forssmann WG, Luss H, Meyer M. Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J. 2006;27:2823-32.
44. Luss H, Mitrovic V, Seferovic PM, Simeunovic D, Ristic AD, Moiseyev VS, Forssmann WG, Hamdy AM, Meyer M. Renal effects of ularitide in patients with decompensated heart failure. Am Heart J. 2008;155:1012.e1-1012.e8. doi: 10.1016/j.ahj.2008.02.011.
45. Del Ry S, Passino C, Emdin M, Giannessi D. C-type natriuretic peptide and heart failure. Pharmacol Res. 2006;54:326-33.
46. Stingo AJ, Clavell AL, Heublein DM, Wei CM, Pittelkow MR, Burnett Jr JC. Presence of c-type natriuretic peptide in cultured human endothelial cells and plasma. Am J Physiol. 1992;263:H1318-21.
47. Wei CM, Heublein DM, Perrella MA, Lerman A, Rodeheffer RJ, McGregor CG, Edwards WD, Schaff HV, Burnett Jr JC. Natriuretic peptide system in human heart failure. Circulation. 1993;88:1004-9.
48. Kalra PR, Clague JR, Bolger AP, Anker SD, Poole-Wilson PA, Struthers AD, Coats AJ. Myocardial production of c-type natriuretic peptide in chronic heart failure. Circulation. 2003;107:571-3.
49. Horio T, Tokudome T, Maki T, Yoshihara F, Suga S, Nishikimi T, Kojima M, Kawano Y, Kangawa K. Gene expression, secretion, and autocrine action of c-type natriuretic peptide in cultured adult rat cardiac fibroblasts. Endocrinology. 2003;144:2279-84.
50. Nazario B, Hu RM, Pedram A, Prins B, Levin ER. Atrial and brain natriuretic peptides stimulate the production and secretion of c-type natriuretic peptide from bovine aortic endothelial cells. J Clin Invest. 1995;95:1151-7.
51. Stingo AJ, Clavell AL, Aarhus LL, Burnett Jr JC. Cardiovascular and renal actions of c-type natriuretic peptide. Am J Physiol. 1992;262:H308-12.
52. Wei CM, Aarhus LL, Miller VM, Burnett Jr JC. Action of c-type natriuretic peptide in isolated canine arteries and veins. Am J Physiol. 1993;264:H71-3.
53. Banks M, Wei CM, Kim CH, Burnett Jr JC, Miller VM. Mechanism of relaxations to c-type natriuretic peptide in veins. Am J Physiol. 1996;271:H1907-11.
54. Garbers DL, Chrisman TD, Wiegn P, Katafuchi T, Albanesi JP, Bielinski V, Barylko B, Redfield MM, Burnett Jr JC. Membrane guanylyl cyclase receptors: an update. Trends Endocrinol Metab. 2006;17:251-8.
55. Qian JY, Haruno A, Asada Y, Nishida T, Saito Y, Matsuda T, Ueno H. Local expression of c-type natriuretic peptide suppresses inflammation, eliminates shear stress-induced thrombosis, and prevents neointima formation through enhanced nitric oxide production in rabbit injured carotid arteries. Circ Res. 2002;91:1063-9.
56. Hunt PJ, Richards AM, Espiner EA, Nicholls MG, Yandle TG. Bioactivity and metabolism of c-type natriuretic peptide in normal man. J Clin Endocrinol Metab. 1994;78:1428-35.
57. Chauhan SD, Nilsson H, Ahluwalia A, Hobbs AJ. Release of c-type natriuretic peptide accounts for the biological activity of endothelium-derived hyperpolarizing factor. Proc Natl Acad Sci U S A. 2003;100:1426-31.
58. Cargill RI, Barr CS, Coutie WJ, Struthers AD, Lipworth BJ. C-type natriuretic peptide levels in cor pulmonale and in congestive heart failure. Thorax. 1994;49:1247-9.
59. Del Ry S, Passino C, Maltinti M, Emdin M, Giannessi D. C-type natriuretic peptide plasma levels increase in patients with chronic heart failure as a function of clinical severity. Eur J Heart Fail. 2005;7:1145-8.
60. Del Ry S, Maltinti M, Emdin M, Passino C, Catapano G, Giannessi D. Radioimmunoassay for plasma c-type natriuretic peptide determination: a methodological evaluation. Clin Chem Lab Med. 2005;43:641-5.
61. Del Ry S, Cabiati M, Stefano T, Catapano G, Caselli C, Prescimone T, Passino C, Emdin M, Giannessi D. Comparison of nt-procnp and cnp plasma levels in heart failure, diabetes and cirrhosis patients. Regul Pept. 2011;166:15-20.
62. Palmer SC, Prickett TC, Espiner EA, Yandle TG, Richards AM. Regional release and clearance of c-type natriuretic peptides in the human circulation and relation to cardiac function. Hypertension. 2009;54:612-8.
63. Lisy O, Lainchbury JG, Leskinen H, Burnett Jr JC. Therapeutic actions of a new synthetic vasoactive and natriuretic peptide, dendroaspis natriuretic peptide, in experimental severe congestive heart failure. Hypertension. 2001;37:1089-94.
64. Lisy O, Jougasaki M, Heublein DM, Schirger JA, Chen HH, Wennberg PW, Burnett JC. Renal actions of synthetic dendroaspis natriuretic peptide. Kidney Int. 1999;56:502-8.
65. Dickey DM, Burnett Jr JC, Potter LR. Novel bifunctional natriuretic peptides as potential therapeutics. J Biol Chem. 2008;283:35003-9.
66. Dickey DM, Potter LR. Dendroaspis natriuretic peptide and the designer natriuretic peptide, cd-np, are resistant to proteolytic inactivation. J Mol Cell Cardiol. 2011;51:67-71.
67. Lee CY, Chen HH, Lisy O, Swan S, Cannon C, Lieu HD, Burnett Jr JC. Pharmacodynamics of a novel designer natriuretic peptide, cd-np, in a first-in-human clinical trial in healthy subjects. J Clin Pharmacol. 2009;49:668-73.
68. Lisy O, Huntley BK, McCormick DJ, Kurlansky PA, Burnett Jr JC. Design, synthesis, and actions of a novel chimeric natriuretic peptide: Cd-np. J Am Coll Cardiol. 2008;52:60-8.
69. Lieu H, Goldsmith S, Neutal J, Massie BM, Burnett J. Initial observations of intravenous cd-np, chimeric natriuretic peptide, on renal functions in chronic heart failure patients. J Card Fail. 2009;15:S77.
70. Neutel J, Rolston W, Maddock S, Goldsmith S, Koren M, Antwerp BV, Burnett J, Lieu HD. Initial experience with subcutaneous infusion of cenderitide in patients with chronic heart failure. JACC. 2012;59:E1037.
71. •• Mitrovic V, Jovanovic A, Lehinant S. Soluble guanylate cyclase modulators in heart failure. Curr Heart Fail Rep. 2011;8:38-44. An excellent review of the sGC system.
72. Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, Ak HS, Meurer S, Deile M, Taye A, Knorr A, Lapp H, Muller H, Turgay Y, Rothkegel C, Tersteegen A, Kemp-Harper B, Muller-Esterl W, Schmidt HH. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest. 2006;116:2552-61.
73. Lip GY, Pearce LA, Chin BS, Conway DS, Hart RG. Effects of congestive heart failure on plasma von willebrand factor and soluble p-selectin concentrations in patients with non-valvar atrial fibrillation. Heart. 2005;91:759-63.
74. Fischer D, Rossa S, Landmesser U, Spiekermann S, Engberding N, Hornig B, Drexler H. Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death. Eur Heart J. 2005;26:65-9.
75. Hingorany S, Frishman WH. Soluble guanylate cyclase activation with cinaciguat: a new approach to the treatment of decompensated heart failure. Cardiol Rev. 2011;19:23-9.
76. Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation. 2005;111:363-8.
77. Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HH, Stasch JP. No-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov. 2006;5:755-68.
78. Melichar VO, Behr-Roussel D, Zabel U, Uttenthal LO, Rodrigo J, Rupin A, Verbeuren TJ, Kumar HSA, Schmidt HH. Reduced cgmp signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis. Proc Natl Acad Sci U S A. 2004;101:16671-6.
79. Abrams J. Beneficial actions of nitrates in cardiovascular disease. Am J Cardiol. 1996;77:31C-7C.
80. Munzel T, Daiber A, Mulsch A. Explaining the phenomenon of nitrate tolerance. Circ Res. 2005;97:618-28.
81. Dikalov S, Fink B, Skatchkov M, Stalleicken D, Bassenge E. Formation of reactive oxygen species by pentaerithrityltetranitrate and glyceryl trinitrate in vitro and development of nitrate tolerance. J Pharmacol Exp Ther. 1998;286:938-44.
82. Hink U, Oelze M, Kolb P, Bachschmid M, Zou MH, Daiber A, Mollnau H, August M, Baldus S, Tsilimingas N, Walter U, Ullrich V, Munzel T. Role for peroxynitrite in the inhibition of prostacyclin synthase in nitrate tolerance. J Am Coll Cardiol. 2003;42:1826-34.
83. Boerrigter G, Burnett Jr JC. Soluble guanylate cyclase: Not a dull enzyme. Circulation. 2009;119:2752-4.
84. Stasch JP, Schmidt P, Alonso-Alija C, Apeler H, Dembowsky K, Haerter M, Heil M, Minuth T, Perzborn E, Pleiss U, Schramm M, Schroeder W, Schroder H, Stahl E, Steinke W, Wunder F. No- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol. 2002;136:773-83.
85. Frey R, Muck W, Unger S, Artmeier-Brandt U, Weimann G, Wensing G. Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (bay 58-2667) in healthy male volunteers. J Clin Pharmacol. 2008;48:1400-10.
86. Lapp H, Mitrovic V, Franz N, Heuer H, Buerke M, Wolfertz J, Mueck W, Unger S, Wensing G, Frey R. Cinaciguat (bay 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation. 2009;119:2781-8.
87. Erdmann E, Semigran MJ, Nieminen MS, Gheorghiade M, Agrawal R, Mitrovic V, Mebazaa A. Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure. Eur Heart J. 2012; doi: 10.1093/eurheartj/ehs196.
88. • Gheorghiade M, Greene SJ, Filippatos G, Erdmann E, Ferrari R, Levy PD, Maggioni A, Nowack C, Mebazaa A. Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase iib compose programme in acute heart failure syndromes. Eur J Heart Fail. 2012;14:1056-66. Results of the COMPOSE program, a series of studies on the use of cinaciguat in heart failure that showed an excess of hypotension with its use.
89. Ghofrani HA, Hoeper MM, Halank M, Meyer FJ, Staehler G, Behr J, Ewert R, Weimann G, Grimminger F. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase ii study. Eur Respir J. 2010;36:792-9.
90. Grimminger F, Weimann G, Frey R, Voswinckel R, Thamm M, Bolkow D, Weissmann N, Muck W, Unger S, Wensing G, Schermuly RT, Ghofrani HA. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J. 2009;33:785-92.
91. Ghio S, Bonderman D, Felix SB, Ghofrani HA, Michelakis ED, Mitrovic V, Oudiz RJ, Frey R, Roessig L, Semigran MJ. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (lepht): rationale and design. Eur J Heart Fail. 2012;14:946-53.
92. Samuel CS, Du XJ, Bathgate RA, Summers RJ. 'Relaxin' The stiffened heart and arteries: the therapeutic potential for Relaxin in the treatment of cardiovascular disease. Pharmacol Ther. 2006;112:529-52.
93. •• Du XJ, Bathgate RA, Samuel CS, Dart AM, Summers RJ. Cardiovascular effects of Relaxin: from basic science to clinical therapy. Nat Rev Cardiol. 2010;7:48-58. An excellent review on the mechanism of action for relaxin.
94. Novak J, Parry LJ, Matthews JE, Kerchner LJ, Indovina K, Hanley-Yanez K, Doty KD, Debrah DO, Shroff SG, Conrad KP. Evidence for local relaxin ligand-receptor expression and function in arteries. FASEB J. 2006;20:2352-62.
95. Dschietzig T, Richter C, Bartsch C, Laule M, Armbruster FP, Baumann G, Stangl K. The pregnancy hormone relaxin is a player in human heart failure. FASEB J. 2001;15:2187-95.
96. Teichman SL, Unemori E, Teerlink JR, Cotter G, Metra M. Relaxin: review of biology and potential role in treating heart failure. Curr Heart Fail Rep. 2010;7:75-82.
97. Hsu SY, Nakabayashi K, Nishi S, Kumagai J, Kudo M, Sherwood OD, Hsueh AJ. Activation of orphan receptors by the hormone relaxin. Science. 2002;295:671-4.
98. Halls ML, Bathgate RA, Summers RJ. Relaxin family peptide receptors rxfp1 and rxfp2 modulate camp signaling by distinct mechanisms. Mol Pharmacol. 2006;70:214-26.
99. Conrad KP, Novak J. Emerging role of relaxin in renal and cardiovascular function. Am J Physiol Regul Integr Comp Physiol. 2004;287:R250-61.
100. Bani D, Failli P, Bello MG, Thiemermann C, Bani Sacchi T, Bigazzi M, Masini E. Relaxin activates the l-arginine-nitric oxide pathway in vascular smooth muscle cells in culture. Hypertension. 1998;31:1240-7.
101. Jeyabalan A, Novak J, Danielson LA, Kerchner LJ, Opett SL, Conrad KP. Essential role for vascular gelatinase activity in relaxin-induced renal vasodilation, hyperfiltration, and reduced myogenic reactivity of small arteries. Circ Res. 2003;93:1249-57.
102. Fernandez-Patron C, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res. 1999;85:906-11.
103. Jeyabalan A, Shroff SG, Novak J, Conrad KP. The vascular actions of relaxin. Adv Exp Med Biol. 2007;612:65-87.
104. Dschietzig T, Bartsch C, Stangl V, Baumann G, Stangl K. Identification of the pregnancy hormone relaxin as glucocorticoid receptor agonist. FASEB J. 2004;18:1536-8.
105. Samuel CS, Zhao C, Bathgate RA, Du XJ, Summers RJ, Amento EP, Walker LL, McBurnie M, Zhao L, Tregear GW. The Relaxin gene-knockout mouse: a model of progressive fibrosis. Ann N Y Acad Sci. 2005;1041:173-81.
106. Dschietzig T, Teichman S, Unemori E, Wood S, Boehmer J, Richter C, Baumann G, Stangl K. Intravenous recombinant human Relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial. J Card Fail. 2009;15:182-90.
107. Teerlink JR, Metra M, Felker GM, Ponikowski P, Voors AA, Weatherley BD, Marmor A, Katz A, Grzybowski J, Unemori E, Teichman SL, Cotter G. Relaxin for the treatment of patients with acute heart failure (pre-relax-ahf): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase iib study. Lancet. 2009;373:1429-39.
108. •• Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF, Jr., Dorobantu MI, Grinfeld LR, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin TM, Metra M. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (relax-ahf): A randomised, placebo-controlled trial. Lancet. 2012; doi: 10.1016/S0140-6736(12) 61855-8. Recent positive trial assessing the impact of relaxin on acute decompensated heart failure.
109. Metra M, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF, Jr., Dorobantu MI, Grinfeld L, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Prescott MF, Edwards C, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin T, Teerlink JR. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the relaxin in acute heart failure (relax-ahf) development program: correlation with outcomes. J Am Coll Cardiol. 2013;61:196-206.
110. Konstam MA. Relax-ahf: rising from the doldrums in acute heart failure. Lancet. 2012; doi: 10.1016/S0140-6736(12)61896-0.